Trial Update October 15, 2026

Insulin Aspart 30 Biosimilarity Trial Registered, Not Yet Recruiting

A clinical trial involving insulin aspart was registered on October 15, 2026. The study, titled "Comparison of the Pharmacokinetic (PK) and Pharmacodynamic (PD) Biosimilarity of Insulin Aspart 30 Injections After Single-Dose Subcutaneous Administration to Healthy Volunteers," is listed under identifier NCT07875803.

The trial's current status is not yet recruiting. No phase designation has been assigned to this study. The trial is designed to compare pharmacokinetic and pharmacodynamic biosimilarity of Insulin Aspart 30 injections following a single subcutaneous dose in healthy volunteers.

No results or outcome data have been posted for this trial at this time. The information available reflects only the trial's registration and planned design as of the listed date. Further updates on recruitment status, enrollment, or results would be expected as the study progresses through standard clinical trial reporting channels.

Insulin aspart is an approved compound. Readers interested in background information on this compound can consult the compound overview for additional context.

See the full insulin aspart overview

Source: https://clinicaltrials.gov/study/NCT07875803